Celebrex - Revision history

Lazy at 08:21, 18 January 2025

2025-01-18T08:21:07Z

← Older revision		Revision as of 01:21, 18 January 2025
Line 59:		Line 59:
	\|links=		\|links=
	\|toxicity_explanation=The toxicity level of 2.5 indicates that Celecoxib (Celebrex) and other NSAIDs have a moderate level of side effects, which are mostly related to potential stomach issues with long-term use. However, Celebrex has been designed to minimize these issues. Even though their use in cancer treatment is experimental, these drugs are generally well-tolerated. A toxicity level of 5 would represent a treatment with severe and frequent side effects.		\|toxicity_explanation=The toxicity level of 2.5 indicates that Celecoxib (Celebrex) and other NSAIDs have a moderate level of side effects, which are mostly related to potential stomach issues with long-term use. However, Celebrex has been designed to minimize these issues. Even though their use in cancer treatment is experimental, these drugs are generally well-tolerated. A toxicity level of 5 would represent a treatment with severe and frequent side effects.
	}}		\|overview=Celebrex (Celecoxib) is an FDA-approved NSAID primarily used for arthritis and pain management, but it is being investigated for its potential anti-inflammatory and anti-cancer properties in treating various cancers. While early clinical trials show mixed results regarding its efficacy when combined with conventional cancer therapies, ongoing research continues to explore its mechanisms of action and the potential benefits it may provide in cancer treatment protocols.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:31:56Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:31, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=The use of Celebrex and other NSAIDs in cancer treatment is based on their anti-inflammatory properties, inhibition of COX-2 enzymes, and subsequent reduction in angiogenesis and tumor growth. While preclinical and early clinical research indicates potential benefits, including immune system enhancement and apoptosis induction, results from clinical trials have been mixed. The mechanisms underlying NSAIDs' anti-cancer effects, particularly in gliomas, suggest a promising avenue for research, emphasizing the need for further large-scale, randomized clinical trials to better understand their efficacy and optimal integration into cancer therapy regimens.		\|notes=The use of Celebrex and other NSAIDs in cancer treatment is based on their anti-inflammatory properties, inhibition of COX-2 enzymes, and subsequent reduction in angiogenesis and tumor growth. While preclinical and early clinical research indicates potential benefits, including immune system enhancement and apoptosis induction, results from clinical trials have been mixed. The mechanisms underlying NSAIDs' anti-cancer effects, particularly in gliomas, suggest a promising avenue for research, emphasizing the need for further large-scale, randomized clinical trials to better understand their efficacy and optimal integration into cancer therapy regimens.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_level=2.5		\|toxicity_level=2.5
	\|book_text=Celebrex (and other NSAIDs)		\|book_text=Celebrex (and other NSAIDs)

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:13Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 58:		Line 58:

	\|links=		\|links=
			\|toxicity_explanation=The toxicity level of 2.5 indicates that Celecoxib (Celebrex) and other NSAIDs have a moderate level of side effects, which are mostly related to potential stomach issues with long-term use. However, Celebrex has been designed to minimize these issues. Even though their use in cancer treatment is experimental, these drugs are generally well-tolerated. A toxicity level of 5 would represent a treatment with severe and frequent side effects.
	}}		}}

Lazy at 09:03, 26 March 2024

2024-03-26T09:03:18Z

@@ Line 10: / Line 10: @@
 |notes=The use of Celebrex and other NSAIDs in cancer treatment is based on their anti-inflammatory properties, inhibition of COX-2 enzymes, and subsequent reduction in angiogenesis and tumor growth. While preclinical and early clinical research indicates potential benefits, including immune system enhancement and apoptosis induction, results from clinical trials have been mixed. The mechanisms underlying NSAIDs' anti-cancer effects, particularly in gliomas, suggest a promising avenue for research, emphasizing the need for further large-scale, randomized clinical trials to better understand their efficacy and optimal integration into cancer therapy regimens.
 |category=Repurposed Drugs
 |links=
 }}

Lazy: Created page with "{{TreatmentInfo |drug_name=Celebrex (Celecoxib) and Other NSAIDs |FDA_approval=Yes (Celebrex is FDA-approved for arthritis and pain, but not specifically for cancer treatment) |used_for=Investigational use in cancer treatment due to anti-inflammatory, anti-angiogenic, and potential tumor growth inhibition properties |clinical_trial_phase=Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments |commo..."

2024-03-23T21:37:58Z

Created page with "{{TreatmentInfo |drug_name=Celebrex (Celecoxib) and Other NSAIDs |FDA_approval=Yes (Celebrex is FDA-approved for arthritis and pain, but not specifically for cancer treatment) |used_for=Investigational use in cancer treatment due to anti-inflammatory, anti-angiogenic, and potential tumor growth inhibition properties |clinical_trial_phase=Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments |commo..."

New page

{{TreatmentInfo
|drug_name=Celebrex (Celecoxib) and Other NSAIDs
|FDA_approval=Yes (Celebrex is FDA-approved for arthritis and pain, but not specifically for cancer treatment)
|used_for=Investigational use in cancer treatment due to anti-inflammatory, anti-angiogenic, and potential tumor growth inhibition properties
|clinical_trial_phase=Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments
|common_side_effects=Generally well-tolerated; potential gastrointestinal issues with long-term use of some NSAIDs. Celebrex designed to minimize COX-1 inhibition and related stomach issues.
|OS_with=Not specifically documented; clinical trials have shown mixed results, with some indicating significant benefit when added to standard chemotherapy protocols
|PFS_with=Variable across studies; for example, a study combining Temodar with Celebrex showed a PFS-6 of 35%, another combining Celebrex with CPT-11 showed PFS-6 of 25%
|usefulness_rating=3
|notes=The use of Celebrex and other NSAIDs in cancer treatment is based on their anti-inflammatory properties, inhibition of COX-2 enzymes, and subsequent reduction in angiogenesis and tumor growth. While preclinical and early clinical research indicates potential benefits, including immune system enhancement and apoptosis induction, results from clinical trials have been mixed. The mechanisms underlying NSAIDs' anti-cancer effects, particularly in gliomas, suggest a promising avenue for research, emphasizing the need for further large-scale, randomized clinical trials to better understand their efficacy and optimal integration into cancer therapy regimens.
|category=Repurposed Drugs
|links=
}}